Madrigal Pharmaceuticals, Inc. (MDGL) Stock Ticker
Market factors today
Unlock the full MDGL picture
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL stock facts
| Ticker symbol | MDGL |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $11.9B |
| CEO | William J. Sibold |
| Employees | 915 |
| Headquarters | West Conshohocken, PA, US |
| IPO date | 2007-02-06 |
| Website | www.madrigalpharma.com |
What you can see for MDGL on Tickr
Live MDGL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MDGL report.
Rankings
FAQ
What is the ticker symbol for Madrigal Pharmaceuticals, Inc.?
The ticker symbol for Madrigal Pharmaceuticals, Inc. is MDGL, listed on the NASDAQ Global Select.
What is MDGL?
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III)…